This post is co-written by Amar Goel, co-founder and CEO of Bito. Meticulous code review is a critical step in the software development process, one that helps delivery high-quality code that’s ready for enterprise use. However, it can be a time-consuming process at scale, when experts must review thousands ofContinue Reading
This post is co-authored with Sundeep Sardana, Malolan Raman, Joseph Lam, Maitri Shah and Vaibhav Singh from Verisk. Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry, empowering clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud, and makeContinue Reading
Building cloud infrastructure based on proven best practices promotes security, reliability and cost efficiency. To achieve these goals, the AWS Well-Architected Framework provides comprehensive guidance for building and improving cloud architectures. As systems scale, conducting thorough AWS Well-Architected Framework Reviews (WAFRs) becomes even more crucial, offering deeper insights and strategicContinue Reading
Government and non-profit organizations evaluating grant proposals face a significant challenge: sifting through hundreds of detailed submissions, each with unique merits, to identify the most promising initiatives. This arduous, time-consuming process is typically the first step in the grant management process, which is critical to driving meaningful social impact. TheContinue Reading
Customer reviews can reveal customer experiences with a product and serve as an invaluable source of information to the product teams. By continually monitoring these reviews over time, businesses can recognize changes in customer perceptions and uncover areas of improvement. Analyzing these reviews to extract actionable insights enables data-driven decisionsContinue Reading
Dmitry Vinogradov Glaukos Corporation (NYSE:GKOS) traded lower on Wednesday after Citi downgraded the glaucoma product maker to neutral from buy as part of a review of its U.S. MedTech coverage ahead of Q2 2024 results. Analyst Joanne Wuensch argued that Glaukos (GKOS), which has climbed more than 50% this year,Continue Reading
